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Strengths and limitations of this study
 ► This systematic review will provide a comprehen-
sive search of the literature regarding risk and 
protective factors of dementia among adults with 
post- traumatic stress disorder (PTSD).
 ► Experts in the field of cognitive decline, mild cogni-
tive impairment, all- type dementia and PTSD devel-
oped and guided the search strategy.
 ► An exhaustive search of multiple databases (ie, 
PubMed, CINAHL, PsychINFO, The Cochrane Library, 
Scopus and ProQuest Dissertation and Theses 
Global) will be performed to ensure a comprehen-
sive review, yet, potentially relevant articles from 
other/additional databases may be missed.
 ► Given that this review will be restricted to obser-
vational studies with 300 or more participants and 
randomised controlled trials with 50 or more partici-
pants, relevant studies with important evidence may 
be missed, for example, from studies with smaller 
samples.
 ► Another potential limitation may be that a meta- 
analysis may not be conducted due to included stud-
ies being insufficiently homogenous, in which case a 
narrative approach will be used.
AbStrACt
Introduction Post- traumatic stress disorder (PTSD) 
is associated with an increased risk of dementia. 
Individual epidemiological studies have controlled for 
several confounders of the relationship between PTSD 
and increased dementia risk, yet particular risk factors 
underlying this relationship have not been determined. 
This systematic review protocol aims to identify risk and 
protective factors of dementia among adults with PTSD.
Methods and analysis We will conduct an electronic 
search of the databases: PubMed, CINAHL, PsychINFO, The 
Cochrane Library, Scopus and ProQuest Dissertation and 
Theses Global. After screening the studies, quantitative 
synthesis will be performed, if possible. Otherwise, a 
narrative synthesis will be performed. We will include 
randomised controlled trials and other types of research 
evidence including longitudinal cohort studies. Strength 
of evidence will be assessed using the Grading of 
Recommendations, Assessment, Development and 
Evaluations method. Examples of variables that will 
be extracted are: year of PTSD diagnosis, comorbid 
conditions, health behaviours, pharmacological treatments 
and year of mild cognitive impairment or dementia 
diagnosis. We developed this systematic review protocol 
according to the Preferred Reporting Items for Systematic 
Review and Meta- Analysis Protocols 2015 statement.
Ethics and dissemination The proposed study will 
not collect individual- level data and, therefore, does not 
require ethical approval. Results of this study will provide 
current evidence on risk and protective factors of dementia 
in adults with PTSD. Findings will be disseminated in peer- 
reviewed publications and conference presentations.
PrOSPErO registration number CRD42019128553.
IntrOduCtIOn
Post- traumatic stress disorder (PTSD) is a 
psychiatric syndrome that may develop in 
individuals who have experienced a trau-
matic event1 (eg, war, sexual assault, accident 
or environmental catastrophe) resulting in 
symptoms of intrusive thoughts, avoidance of 
trauma- related stimuli, negative alterations in 
cognition or mood and changes in arousal.2 
PTSD is characterised clinically by four groups 
of related symptoms, also known as ‘symptom 
clusters’, including: (1) intrusive thoughts 
(eg, feelings of re- experiencing the event, 
memories, dreams or flashbacks), (2) avoid-
ance of trauma- related stimuli (eg, distressing 
internal reminders such as thoughts, memo-
ries or feelings and distressing external 
reminders such as people, places, conversa-
tions or objects), (3) negative alterations in 
cognition or mood (eg, inability to remember 
aspects of the traumatic event, negative 
beliefs about self or others, persistent nega-
tive emotional state, feelings of detachment 
or anhedonia) and (4) changes in arousal 
(eg, irritable or angry outbursts, exaggerated 
startle response, hypervigilance, problems 
concentrating, sleep disturbance).2 Overall, 
about 8.6 million US adults or 5.7% of the 
population, aged 18–64 years, are diagnosed 
with PTSD at some point in their lifetime.3 4 
Research over the last decade has indicated 
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that a subset of individuals with PTSD is at greater risk for 
developing all- type dementia.
Epidemiological evidence from studies of military 
veterans5–7 and civilians8 9 has revealed that individuals 
with PTSD have up to a fourfold greater risk of devel-
oping dementia than those without PTSD. However, it 
remains unclear how PTSD leads to cognitive decline 
and development of dementia. Within the general popu-
lation, experts have identified several protective factors 
associated with decreased dementia risk (eg, physical 
activity, cognitive training, Mediterranean diet and vege-
table intake).10 Such health behaviours may be more 
common in adults with PTSD who do not develop mild 
cognitive impairment (MCI) or dementia. Conversely, 
factors associated with increased dementia risk, such as 
genetic factors (eg, being homozygous for APOE ε4), 
negative health behaviours (eg, tobacco use), psychiatric 
disorders (eg, major depressive disorder), use of certain 
pharmaceutical medications (eg, benzodiazepines) and 
medical history (eg, stroke),11 may occur more frequently 
in persons with PTSD who develop MCI or dementia.
However, it is also possible that PTSD confers neuro-
biological changes that contribute to the pathogen-
esis of dementia. While an association between PTSD 
and impaired cognitive performance has been estab-
lished,12–16 whether the cognitive effects of PTSD symp-
toms are mechanistically linked to the later development 
of dementia is a significant gap in knowledge. In prior 
retrospective cohort research on dementia incidence in 
veterans with and without PTSD that controlled for several 
confounding factors, findings indicated that a history of 
head injury, substance misuse and clinical depression 
were not responsible for the increased dementia risk in 
persons with PTSD.6 Interestingly, a prospective cohort 
study of World Trade Center first- responders who devel-
oped PTSD revealed that the intrusive thoughts, symptom 
cluster of PTSD, was consistently predictive of cognitive 
impairment 14 years later.17 This finding suggests that 
exposure to PTSD itself may be a risk factor for dementia. 
It remains unclear, however, which particular risk factors 
account for the increased risk of dementia in the PTSD 
population. Addressing this knowledge gap, we will 
examine exposure to PTSD symptoms and previously 
identified risk and protective factors associated with MCI 
and all types of dementia among those with PTSD.
In a conceptualisation of cognition as a continuum 
of indiscrete, overlapping degrees of functional ability, 
normal cognition would sit at the left end, followed 
by cognitive decline, MCI, and non- specific dementia 
and Alzheimer’s disease (AD) at the right end of the 
continuum. Experts consider some degree of cognitive 
decline as a normal part of the ageing process. MCI is set 
apart from normal age- related cognitive decline in that 
the degree of decline is greater than expected, consid-
ering the person’s age and educational background, yet 
impairment is not severe enough to meet criteria for a 
diagnosis of dementia. Extant research on the stages of 
cognitive decline leading to dementia indicates that as 
early as mid- life, alterations in the brain are detectable by 
imaging and other biomarkers18–20 introducing a poten-
tial opportunity for targeting modifiable risk and protec-
tive factors of dementia. However, the implementation of 
screening and detection of cognitive decline in the PTSD 
population as a means to facilitate early detection and 
delay or prevention of dementia is another area in need 
of research.
Researchers in the field of geriatric mental health 
have identified several gaps in the care of older adults 
with PTSD. Relative to younger adults, PTSD among 
older adults is under- identified, under- treated and under- 
researched.21 Furthermore, conventional evidence- based 
PTSD treatments do not specifically focus on main-
taining cognitive health. Given the increased prevalence 
of dementia in the PTSD population in conjunction 
with the fact that brain changes associated with cogni-
tive decline start long before symptoms are evident,22 an 
assessment of risk and protective factors could be used 
by clinicians to augment PTSD treatment of middle- aged 
adults in service of supporting cognitive health. Thus, the 
overarching research question to be addressed is: ‘What 
are risk and protective factors of dementia among adults 
with PTSD?’
Objectives
This systematic review aims to critically appraise the 
research on risk and protective factors of MCI/dementia 
among adults with PTSD. Potential and anticipated 
risk factors may include well- known comorbidities of 
PTSD, such as major depressive disorder,23 substance 
use disorder,24 obesity25 and other associated genetic or 
biological factors (ie, APOE genotype26 or female sex,27 
respectively). Potential and anticipated protective factors 
may include cognitive training or physical exercise. 
Several of the aforementioned factors, among others, 
are also associated with risk and prevention of dementia, 
respectively.28–36 Therefore, the following two questions 
will be addressed within a comparative context. Among 
adults with PTSD, comparisons will be made between 
those who did and did not develop MCI or dementia.
1. What are the recency, severity and duration of PTSD 
exposure?
2. What is the exposure (dose, frequency, duration) of 




This systematic review will be based on the approach 
proposed by Joanna Briggs Institute37 and will build on 
a prior systematic review of risk and protective factors for 
dementia among the general population.10 37 The former 
describes an approach toward systematic reviews, in which 
a search is conducted for the ‘best available’ evidence.
The search strategy will be guided by the Preferred 
Reporting Items for Systematic Review and Meta- Analysis 
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Protocols (PRISMA- P)38. PRISMA- P is a search protocol 
for systematic reviews and meta- analyses, which includes 
an evidence- based minimum number of items for 
reporting. The search strategy (see online supplementary 
appendix A) aims to locate both published and unpub-
lished studies, as well as grey literature. Medical subject 
headings and text words related to PTSD, cognitive 
decline, MCI, dementia, and risk and protective factors 
(based on a prior systematic review by Plassman and 
colleagues10) were used to develop a search strategy.
Search for and identification of studies
The following databases will be searched: PubMed, 
CINAHL, PsychINFO, The Cochrane Library and Scopus. 
Additionally, we will search ProQuest Dissertations and 
Theses Global for grey literature and unpublished studies. 
We will limit our literature search to the English language 
and human subjects. To guarantee literature satisfaction, 
the references of included articles, identified through the 
search, will be scanned.
Eligibility criteria
Studies on adults, with an average age of 50 years and older 
at follow- up, who have been diagnosed with PTSD will be 
included, given that neurodegenerative changes can be 
observed before the age of 60.39 40 Because the identified 
problem is the increased prevalence of dementia in older 
adults with PTSD, comparators are adults aged 50 years 
or over with PTSD (current or past) who do not develop 
MCI or dementia. All racial and ethnic populations will 
be considered.
Epidemiological findings have shown that chronic 
stress and PTSD are both associated with an increased 
incidence of different types of dementia.1 6 7 There-
fore, this study will assess risk and protective factors 
for MCI and all frequent/common causes of dementia 
of all possible aetiologies, including senile dementias, 
vascular dementia, AD, frontotemporal dementia, 
Lewy body dementia and dementia not otherwise spec-
ified. This review will consider observational longitu-
dinal cohort studies with 300 or more participants and 
randomised controlled trials (RCTs) with 50 or more 
participants, in order to include studies with sufficient 
statistical power.37 In addition, for observational studies, 
documentation of cognitive changes over at least 1 year 
will be required for studies on MCI, to provide time for 
the occurrence of clinically meaningful change.10 37 Two 
years will be required for studies of all types of dementia, 
including AD10 37 because of the lengthy prodromal 
phase associated with dementia, especially AD. The 
study outcomes will be a diagnosis of MCI or any type of 
dementia, using acceptable standards. Given that PTSD 
was accepted as a disorder and added to the Diagnostic 
and Statistical Manual of Mental Disorders by the Amer-
ican Psychiatric Association in 1980,41 this systematic 
review will consider any studies published from 1980 
until 29 February 2020.
Patient and public involvement
There was no patient or public involvement in the devel-
opment of this study protocol.
Study selection and data abstraction
Using Covidence software42 and following the protocol 
of Williams and colleagues,37 two reviewers with a third 
tie- breaker reviewer will autonomously screen the titles 
and abstracts yielded by the searches against the inclu-
sion and exclusion criteria. Articles meeting the inclusion 
criteria will subsequently undergo a full- text screening 
performed by three reviewers. The three reviewers will 
read each article and, based on this screening, render 
a decision regarding which articles meet the inclusion 
criteria. Disagreements will be resolved by consensus. The 
review will be completed by 15 December 2020.
data collection process and data items
Data extraction will be performed in duplicate and data 
will be input into evidence tables in Excel, modelled 
on the format of Williams and colleagues.37 The data 
elements to be extracted include descriptors to assess 
applicability, quality elements, intervention and expo-
sure details, and outcomes. More specifically, the data 
items will include: details about the timing of diagnosis 
and duration of follow- up for PTSD, MCI and dementia 
diagnoses and other cognitive outcomes; assessment/
diagnostic instruments used for PTSD and all cogni-
tive outcomes; PTSD total and symptom cluster severity 
scores; participant characteristics such as average age, 
sex, race and education; study methodology including 
sample size and study design; potential predictor factors 
(eg, APOE genotype, prisoner of war status, pharmaceu-
tical medications, cognitive training interventions and 
health behaviours); study findings (eg, ORs and HRs) 
and author conclusions. Disagreements between the two 
reviewers will be resolved by consensus or by obtaining a 
third reviewer’s opinion should the two reviewers fail to 
reach consensus.
Assessment of study bias
Recommendations from Grading of Recommendations, 
Assessment, Development and Evaluations will be followed 
to allow assessment of risk- of- bias, imprecision, inconsis-
tency, indirectness, publication bias, magnitude of effect, 
dose–response gradient and residual confounding.43 This 
approach gives a preliminary score of low to observa-
tional studies and high to RCTs.37 This preliminary score 
can be upgraded by a thorough study design, constancy, 
accuracy and other criteria as described by Williams and 
colleagues.37
Analysis
If studies are of sufficient homogeneity regarding partici-
pants, interventions and outcomes, a meta- analysis will be 
conducted.44 In accordance with the guidelines for quan-
titative synthesis of systematic review evidence,45 a tabular 
summary of findings will be created. This table will include 
extracted variables, information regarding the quality of 
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evidence, and the scale of effect of any interventions and 
outcomes investigated. For this study, the outcomes are 
associations of risk and protective factors with MCI or 
dementia in adults with PTSD.
The purpose of the quantitative synthesis is to integrate 
quantitative findings across studies to achieve a coherent 
synthesis.45 A quantitative analysis can be performed 
through a meta- analysis by computing a quantitative 
summary measure.46 For each study, a single effect size 
will be computed for each risk/protective factor and its 
association with MCI/dementia. Pearson’s r will be used 
for computation of global effect sizes. ORs or risk ratios 
will be converted into Pearson’s r to estimate the global 
effect. In this way, the r statistic can be used to describe 
the association between specific risk and protective 
factors and MCI/dementia.47 Cohen’s guidelines will be 
used to interpret the magnitude of the effect: 0.10=small, 
0.30=medium and 0.50=large.48 A random- effects model 
will be used for the estimation of the global effect. The 
Q- statistic will be used to calculate heterogeneity of effect 
sizes across studies. In addition, the I2 statistic will allow 
computation of the proportion of the observed hetero-
geneity that is due to real variation in effect sizes across 
studies versus that due to sampling error.
Based on a previous systematic review of risk and 
protective factors for dementia,10 included studies may 
differ regarding participants and/or outcomes resulting 
in clinical and statistical heterogeneity. In that case, a 
meta- analytic approach is not recommended in order 
to avoid reporting ambiguous values,44 and a narrative 
approach will be conducted. The narrative approach will 
follow the guidelines of the Cochrane Handbook49 and 
will also incorporate the graphical presentation of data 
in the form of a forest plot, to allow visual analysis of the 
patterns of included studies.50 51
Ethics and dissemination
The proposed study will not collect individual- level data 
and, therefore, does not require ethical approval. The 
results of this systematic review will provide the most up 
to date literature synthesis of risk and protective factors 
of dementia in adults with PTSD. Results will be dissem-
inated through peer- reviewed publications and presenta-
tions at relevant national and international conferences.
dISCuSSIOn
In the USA, one- third of seniors die with dementia. 
Annually, dementia- related care costs have reached 
US$290 billion.52 Epidemiological research has revealed 
that PTSD is associated with increased risk for dementia. 
Even after controlling for comorbidities (eg, head injury) 
and other risk factors (eg, smoking), military veterans,5 6 
first- responders,17 and civilians8 9 with PTSD showed an 
approximately twofold5 and fourfold9 greater risk of devel-
oping all- type dementia, respectively.
While it has been well established that PTSD is associ-
ated with impaired cognitive performance,12–16 whether 
the neurobiological changes associated with PTSD 
account for increased dementia risk is a significant gap in 
knowledge. This systematic review will provide a compre-
hensive search of the literature regarding risk and protec-
tive factors of dementia among adults with PTSD.
In the case of AD, early alterations in the brain can be 
detected by imaging and other biomarkers,18–20 creating 
the potential opportunity for being able to target modifi-
able risk and protective factors of Alzheimer’s dementia. 
Implementation of screening and detection of cognitive 
decline to facilitate early detection and delay or preven-
tion of MCI/non- specific dementia in the PTSD popula-
tion is another area in need of research.
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